Novo Nordisk Shares Slide: Uncertainty Surrounds CagriSema Trial Results
Novo Nordisk’s stock plummets after mixed CagriSema trial results raise doubts about the drug’s efficacy in obesity treatment. Investors question its competitive edge, while analysts debate the long-term impact. The coming months will be crucial for the pharmaceutical giant to restore market confidence.